Hikma Pharmaceuticals (LON:HIK) Price Target Raised to GBX 1,870

Hikma Pharmaceuticals (LON:HIK) had its price target lifted by investment analysts at Citigroup from GBX 1,700 to GBX 1,870 in a research report issued to clients and investors on Wednesday,Digital Look reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price target points to a potential upside of 13.82% from the company’s previous close.

Other equities research analysts also recently issued reports about the stock. Berenberg Bank boosted their target price on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Finally, Jefferies Financial Group lifted their price target on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of GBX 2,060.

Hikma Pharmaceuticals Stock Performance

HIK opened at GBX 1,643 on Wednesday. Hikma Pharmaceuticals has a 1-year low of GBX 1,187 and a 1-year high of GBX 1,865. The company has a market cap of £3.43 billion, a price-to-earnings ratio of 9.08, a PEG ratio of 2.38 and a beta of 0.66. The company’s fifty day moving average price is GBX 1,542.79 and its two-hundred day moving average price is GBX 1,454.39. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57.

Insider Transactions at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Tobias Hestler bought 7,500 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of GBX 1,648 per share, with a total value of £123,600. 22.04% of the stock is owned by company insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.